2015
DOI: 10.1007/s13277-015-3089-8
|View full text |Cite
|
Sign up to set email alerts
|

Overexpression of ANCCA/ATAD2 in endometrial carcinoma and its correlation with tumor progression and poor prognosis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

3
28
0

Year Published

2016
2016
2021
2021

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 29 publications
(31 citation statements)
references
References 18 publications
3
28
0
Order By: Relevance
“…In order to confirm the expression of ATAD2 in various tumors [11, 1619], we performed immunohistochemistry analysis on tissue microarrays (TMA) from multiple cancer types including breast, prostate, gastric, colorectal and lung cancers (Figures 1A and Supplementary Figure S1A). ATAD2 was expressed in all tested tumors independent of their tissue of origin.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…In order to confirm the expression of ATAD2 in various tumors [11, 1619], we performed immunohistochemistry analysis on tissue microarrays (TMA) from multiple cancer types including breast, prostate, gastric, colorectal and lung cancers (Figures 1A and Supplementary Figure S1A). ATAD2 was expressed in all tested tumors independent of their tissue of origin.…”
Section: Resultsmentioning
confidence: 99%
“…In cancer cells ATAD2 has been proposed to function as a transcriptional co-regulator of several oncogenic transcriptional factors including estrogen receptor (ER) [12], androgen receptor (AR) [13], E2F transcriptional factor [10] and Myc [14]. Recently, a number of reports have demonstrated that expression of ATAD2 strongly correlates with poor prognosis in different unrelated tumors including gastric cancer [15], endometrial carcinoma [16], hepatocellular carcinoma [17], ovarian carcinoma [18], breast cancer [11, 19] and lung cancer [11] and hence proposed ATAD2 as a poor prognostic marker. Yet it is unclear whether the transcriptional co-regulator function of ATAD2 is the predominant mechanism of malignancy in tumors of diverse origins.…”
Section: Introductionmentioning
confidence: 99%
“…ATAD2 is overexpressed in a wide variety of cancers, such as colorectal, 25 gastric, 26 endometrial, 27 cervical, 28 and ovarian 29 cancers, in which it increases cell proliferation. Its overexpression is already used as a poor prognosis marker.…”
Section: Bromodomainsmentioning
confidence: 99%
“…Proteins belonging to this family hydrolyse ATP to mediate conformational changes in substrate proteins, resulting in diverse cellular processes 27,28 . ATAD2 plays a key role in cell proliferation and is upregulated as a potential oncogene in cervical, colorectal, breast, and lung cancers [29][30][31][32] . In the budding yeast Saccharomyces cerevisiae, the ATAD2 homologue Yta7 binds to histones and participates in the heterochromatin boundary function in the HMR region, where it counteracts the spread of silencing into the neighbouring euchromatin 33,34 .…”
mentioning
confidence: 99%